Aurie announced that the Aurie Reusable No-Touch Intermittent Catheter System™ has been granted marketing authorization from the U.S. Food and Drug Administration (FDA) through the Class II De Novo ...
Aurie received FDA clearance to market a reusable device designed to lower infection risk for long-term users.
Aurie has announced that the Aurie Reusable No-Touch Intermittent Catheter System has been granted marketing authorization from the U.S. Food and Drug Administration (FDA) through the Class II De Novo ...
The DoJ secured record-breaking False Claims Act recoveries of $6.8 billion in fiscal year 2025, with $76 million from the ...
Intrathecal baclofen (ITB) therapy is an established treatment for severe refractory spasticity. Although a positive ITB ...
Urinary bladder paragangliomas (UBPGLs) are rare neuroendocrine tumours, comprising <0.05% of bladder neoplasms. We report a case of a male in his early 30s presenting with persistent lower abdominal ...
A study conducted during COVID-19 pandemic explored the effects of extending the intervals between implanted vascular access port flushing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results